Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Novartis AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Introduction: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Clinical Trials

Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu

Phase 3

Completed

Conditions: Nasal Congestion
Rhinorrhea
Sneezing
Upper Respiratory Tract Infection

Interventions: Drug: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
Drug: Paracetamol (500 mg) tablets

First Posted Date: 2011-10-07

Last Posted Date: 2017-03-03

Lead Sponsor: Novartis

Target Recruit Count: 341

Registration Number: NCT01448057

Locations: 🇧🇷
Santa Casa De Misericordia De Belo Horizonte - Avenida Francisco Sales 1111, Santa Efigenia, Belo Horizonte/MG, Brazil
🇧🇷
Sociedade Campineira De Educacao E Instrucao - Rodovia Dom Pedro I, KM 136 Parque das Universidades, Campinas/SP, Brazil
🇧🇷
Instituto de Ensino e Pesquisa Clínica do Ceará, Rua Coronel Jucá, 1952 - Dionísio Torres -, Fortaleza/CE, Brazil

and more 3 locations

Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings

Phase 2

Completed

Conditions: Bacterial Infection
Gram-positive Bacterial Infection
Streptococcal Infection

Interventions: Biological: Group B Streptococcus Trivalent Vaccine
Biological: Placebo

First Posted Date: 2011-10-05

Last Posted Date: 2014-09-08

Lead Sponsor: Novartis

Target Recruit Count: 86

Registration Number: NCT01446289

Locations: 🇧🇪
UZ Leuven, Herestraat, Leuven, Belgium
🇧🇪
Regionaal Ziekenhuis Heilig Hart,, Gasthuismolenstraat 31, Tienen, Belgium
🇨🇦
University of British Columbia, Rm B3 25 B, 4500 Oak Street,, Vancouver, British Columbia, Canada

and more 2 locations

Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults

Phase 2

Completed

Conditions: Typhoid Fever

Interventions: Biological: NVGH Vi-CRM197

First Posted Date: 2011-09-22

Last Posted Date: 2014-03-24

Lead Sponsor: Novartis

Target Recruit Count: 51

Registration Number: NCT01438996

Locations: 🇧🇪
Centre for the Evaluation of Vaccination (CEV), Antwerp, Wilrijk, Belgium

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants

Phase 2

Completed

Conditions: Typhoid Fever

Interventions: Biological: Vi-CRM197 vaccine
Biological: Pneumococcal conjugate vaccine
Biological: Vi Polysaccharide (PS) vaccine

First Posted Date: 2011-09-20

Last Posted Date: 2014-04-10

Lead Sponsor: Novartis

Target Recruit Count: 120

Registration Number: NCT01437267

Locations: 🇵🇭
Research Institute for Tropical Medicine (RITM), Alabang, Muntinlupa City, Philippines

Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers

Phase 2

Completed

Conditions: Meningococcal Disease
Meningococcal Meningitis

Interventions: Biological: MenC-CRM ROS
Biological: MenC-CRM EMV
Biological: MenC-CRM LIQ

First Posted Date: 2011-09-15

Last Posted Date: 2017-04-25

Lead Sponsor: Novartis

Target Recruit Count: 992

Registration Number: NCT01434680

Locations: 🇵🇱
NZOZ Bioscience Sp zoo, ul Czerkaska, Bydgoszcz, Poland
🇵🇱
Department Infection Disease ZOZ, Dept Infection Disease ZOZ, Debica, Poland
🇵🇱
Centrum Medyczne Graniczna Sp zoo, ul Graniczna 45, Katowice, Poland

and more 8 locations

Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis

Phase 3

Completed

Conditions: Tinea Pedis

Interventions: Drug: Terbinafine
Drug: Terbinafine Placebo

First Posted Date: 2011-09-13

Last Posted Date: 2013-12-27

Lead Sponsor: Novartis

Target Recruit Count: 290

Registration Number: NCT01433107

Locations: 🇨🇳
Peking University First Hospital, Beijing, China
🇨🇳
Beijing University Hospital N°3, Beijing, China
🇨🇳
The Second Affiliated Hospital of Sun Yat-sen University Guangzhou, Guangdong, China

and more 3 locations

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: GSK2110183
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2011-09-05

Last Posted Date: 2018-08-08

Lead Sponsor: Novartis

Target Recruit Count: 90

Registration Number: NCT01428492

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

Phase 4

Completed

Conditions: Meningococcal Meningitis

Interventions: Biological: Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Biological: MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine

First Posted Date: 2011-08-29

Last Posted Date: 2014-02-14

Lead Sponsor: Novartis

Target Recruit Count: 801

Registration Number: NCT01424644

Locations: 🇺🇸
Birmingham Pediatrics, 806 Saint Vincent's Drive, Suite 615, Birmingham, Alabama, United States
🇺🇸
Prairie Fields Family Medicine, 350 W. 23rd Street, Suite A, Fremont, California, United States
🇺🇸
Madera Family Medical Group, 1111 W. Fourth Street, Madera, California, United States

and more 17 locations

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Phase 3

Completed

Conditions: Meningococcal Disease
Meningococcal Meningitis

Interventions: Biological: Serogroup B meningococcal vaccine

First Posted Date: 2011-08-25

Last Posted Date: 2015-02-20

Lead Sponsor: Novartis

Target Recruit Count: 344

Registration Number: NCT01423084

Locations: 🇦🇺
Royal Children's Hospital, Herston, Queensland, Australia
🇦🇺
AusTrials Pty Ltd-Suites 6, 10 & 11, Peninsula Specialist Centre, Kippa-Ring, Queensland, Australia
🇦🇺
AusTrials Pty Ltd-Suite 5, Level 1, 14 Primrose Street, Sherwood, Queensland, Australia

and more 10 locations

Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan

Phase 3

Completed

Conditions: Bacterial Meningitis

Interventions: Biological: Meningococcal ACWY conjugate vaccine

First Posted Date: 2011-08-05

Last Posted Date: 2014-09-22

Lead Sponsor: Novartis

Target Recruit Count: 341

Registration Number: NCT01410474

Locations: 🇨🇳
Mackay Memorial Hospital,, Taipei, Taiwan, China
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan, China
🇨🇳
Far Eastern Memorial Hospital,, Taipei, Taiwan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy